Therapeutic Advances in Infectious Disease · 2017 · 19 citations · 20 references
Life SciencesMicrobiologyPharmacologyAntimicrobial ResistanceMedical MicrobiologyMicrobial PathogenesisAntibacterial PharmacologyAntibiotic ResistanceAntimicrobial Penetration Into TissuesAntimicrobial PharmacodynamicsResistance In Gram-negative BacteriaBactericidal AgentsBroth MicrodilutionMinimum Inhibitory Concentration DeterminationTopical AntibioticsTopical Antimicrobial AgentsTopical Antimicrobial ApplicationTopical Antimicrobial PreparationsTopical Antimicrobials
OBJECTIVES: (MRSA) is an important health care-associated and community-associated pathogen and causes a large number of infections worldwide. For the purpose of application to topical treatment of MRSA infection, we examined the antimicrobial effects of lysophosphatidylcholine (LPC) on MRSA strains. We also investigated the combination effect of LPC and gentamicin on MRSA growth. METHODS: ) bacteria were measured by the broth microdilution method. The mechanism of LPC-mediated MRSA killing was investigated by membrane permeability analysis with DiSC3(5) fluorescence and growth curve analysis. Lastly, the effects of LPC on gentamicin-induced bactericidal activity were determined in combination treatment studies with 15 gentamicin-resistant MRSA isolates from the skin, nose, or ears. RESULTS: The LPC MIC for Gram-positive bacteria varied between 32 µg/ml and >2048 µg/ml, whereas that for all Gram-negative bacteria was >2048 µg/ml. Consistently, membrane permeability analysis showed that LPC was substantially more effective in inducing membrane permeability in Gram-positive bacteria than in Gram-negative counterparts. Growth curve analysis in cotreatment studies demonstrated that LPC has intrinsic bactericidal effects and can also potentiate gentamicin sensitivity in resistant MRSA strains. CONCLUSIONS: Our study demonstrates that LPC exhibits intrinsic antimicrobial effects and can enhance the antimicrobial effects of gentamicin for resistant MRSA strains, suggesting that LPC may be a beneficial additive in topical antibiotics for superficial skin infections.
20
Catherine Liu, Arnold S. Bayer, Sara E. Cosgrove et al. · Clinical Infectious Diseases · 2011 · 4.2K citations · Full text
Catherine Liu, Arnold S. Bayer, Sara E. Cosgrove et al. · Clinical Infectious Diseases · 2011 · 1.6K citations · Full text